JP6757024B2 - 視覚機能再生剤又は視覚機能低下予防剤 - Google Patents

視覚機能再生剤又は視覚機能低下予防剤 Download PDF

Info

Publication number
JP6757024B2
JP6757024B2 JP2018537436A JP2018537436A JP6757024B2 JP 6757024 B2 JP6757024 B2 JP 6757024B2 JP 2018537436 A JP2018537436 A JP 2018537436A JP 2018537436 A JP2018537436 A JP 2018537436A JP 6757024 B2 JP6757024 B2 JP 6757024B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
disease
seq
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018537436A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2018043707A1 (ja
Inventor
俊英 栗原
俊英 栗原
侑作 堅田
侑作 堅田
洋光 國見
洋光 國見
一男 坪田
一男 坪田
秀樹 神取
秀樹 神取
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keio University
Nagoya Institute of Technology
Original Assignee
Keio University
Nagoya Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio University, Nagoya Institute of Technology filed Critical Keio University
Publication of JPWO2018043707A1 publication Critical patent/JPWO2018043707A1/ja
Application granted granted Critical
Publication of JP6757024B2 publication Critical patent/JP6757024B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018537436A 2016-09-02 2017-09-01 視覚機能再生剤又は視覚機能低下予防剤 Active JP6757024B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016172149 2016-09-02
JP2016172149 2016-09-02
PCT/JP2017/031579 WO2018043707A1 (ja) 2016-09-02 2017-09-01 視覚機能再生剤又は視覚機能低下予防剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020050903A Division JP2020117513A (ja) 2016-09-02 2020-03-23 視覚機能再生剤又は視覚機能低下予防剤

Publications (2)

Publication Number Publication Date
JPWO2018043707A1 JPWO2018043707A1 (ja) 2019-07-25
JP6757024B2 true JP6757024B2 (ja) 2020-09-16

Family

ID=61301215

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018537436A Active JP6757024B2 (ja) 2016-09-02 2017-09-01 視覚機能再生剤又は視覚機能低下予防剤
JP2020050903A Withdrawn JP2020117513A (ja) 2016-09-02 2020-03-23 視覚機能再生剤又は視覚機能低下予防剤
JP2022101163A Active JP7427208B2 (ja) 2016-09-02 2022-06-23 視覚機能再生剤又は視覚機能低下予防剤
JP2024004787A Pending JP2024026791A (ja) 2016-09-02 2024-01-16 視覚機能再生剤又は視覚機能低下予防剤
JP2026007551A Pending JP2026063282A (ja) 2016-09-02 2026-01-20 視覚機能再生剤又は視覚機能低下予防剤

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020050903A Withdrawn JP2020117513A (ja) 2016-09-02 2020-03-23 視覚機能再生剤又は視覚機能低下予防剤
JP2022101163A Active JP7427208B2 (ja) 2016-09-02 2022-06-23 視覚機能再生剤又は視覚機能低下予防剤
JP2024004787A Pending JP2024026791A (ja) 2016-09-02 2024-01-16 視覚機能再生剤又は視覚機能低下予防剤
JP2026007551A Pending JP2026063282A (ja) 2016-09-02 2026-01-20 視覚機能再生剤又は視覚機能低下予防剤

Country Status (6)

Country Link
US (2) US11932679B2 (enExample)
EP (2) EP3508212B1 (enExample)
JP (5) JP6757024B2 (enExample)
CN (5) CN109890404A (enExample)
ES (1) ES3059584T3 (enExample)
WO (1) WO2018043707A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3508212B1 (en) * 2016-09-02 2025-10-22 Keio University Rhodopsin gene therapy for regenerating visual function or for preventing deterioration in visual function
CA3127535A1 (en) * 2019-01-18 2020-07-23 Restore Vision Inc. Preventing, and suppressing progression of, retinal disease, improving visual cognitive behavioral function, and strengthening visual function
WO2021049634A1 (ja) * 2019-09-13 2021-03-18 株式会社レストアビジョン キメラロドプシンをコードする核酸コンストラクト
US11771741B2 (en) 2019-09-13 2023-10-03 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin
CN114729009A (zh) 2019-10-31 2022-07-08 伯尔尼大学 用于眼部基因递送的aav载体变体
WO2022059736A1 (ja) * 2020-09-17 2022-03-24 株式会社レストアビジョン 小胞体ストレスまたはオールトランスレチナールに関連する疾患、障害または症状を治療または予防するため、または網膜厚を保護し、または網膜厚の萎縮もしくは萎縮進行を抑制するための組成物。
CN118717946A (zh) * 2023-03-29 2024-10-01 郑州大学第一附属医院 一种嵌合蛋白在治疗视神经变性疾病中的应用
CN118791624B (zh) * 2023-04-11 2026-04-03 苏州星明优健生物技术有限公司 用于治疗视网膜神经退行性疾病的新型gpcr嵌合视蛋白

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US8470790B2 (en) * 2006-05-04 2013-06-25 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
KR101197129B1 (ko) 2009-09-14 2012-11-07 서강대학교산학협력단 글레오박터 로돕신 및 ａｔｐ 합성효소가 방향성을 갖도록 장착된 ａｔｐ 합성용 조성물
EP3399024A1 (en) 2010-03-17 2018-11-07 The Board of Trustees of The Leland Stanford Junior University Light-sensitive ion-passing molecules
KR101061482B1 (ko) 2010-04-20 2011-09-02 서강대학교산학협력단 카로테노이드가 재구성된 글레오박터 로돕신
EP3486253A1 (en) 2010-11-05 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
AU2014243925B2 (en) * 2013-03-14 2018-12-06 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
US10307492B2 (en) * 2014-03-11 2019-06-04 Wayne State University Modified MGLUR6 promoter and methods of use
EP3508212B1 (en) 2016-09-02 2025-10-22 Keio University Rhodopsin gene therapy for regenerating visual function or for preventing deterioration in visual function
CA3127535A1 (en) * 2019-01-18 2020-07-23 Restore Vision Inc. Preventing, and suppressing progression of, retinal disease, improving visual cognitive behavioral function, and strengthening visual function
WO2021049634A1 (ja) 2019-09-13 2021-03-18 株式会社レストアビジョン キメラロドプシンをコードする核酸コンストラクト
US11771741B2 (en) 2019-09-13 2023-10-03 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin

Also Published As

Publication number Publication date
CN109890404A (zh) 2019-06-14
US20240247049A1 (en) 2024-07-25
ES3059584T3 (en) 2026-03-23
EP3508212A1 (en) 2019-07-10
US20190194294A1 (en) 2019-06-27
EP4653537A3 (en) 2026-01-07
JP2020117513A (ja) 2020-08-06
CN117701605A (zh) 2024-03-15
JP2022126804A (ja) 2022-08-30
EP3508212A4 (en) 2020-05-20
CA3035651A1 (en) 2018-03-08
EP4653537A2 (en) 2025-11-26
JP7427208B2 (ja) 2024-02-05
CN117695375A (zh) 2024-03-15
CN117701604A (zh) 2024-03-15
US11932679B2 (en) 2024-03-19
JP2026063282A (ja) 2026-04-10
JP2024026791A (ja) 2024-02-28
JPWO2018043707A1 (ja) 2019-07-25
EP3508212B1 (en) 2025-10-22
CN117701637A (zh) 2024-03-15
WO2018043707A1 (ja) 2018-03-08

Similar Documents

Publication Publication Date Title
JP7427208B2 (ja) 視覚機能再生剤又は視覚機能低下予防剤
KR20210100746A (ko) 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
CN103814045A (zh) 感光嵌合gpcr蛋白
KR102248420B1 (ko) miR-142-3p의 표적 서열을 포함하는 재조합 벡터
JP7299632B2 (ja) 網膜疾患の予防および進行抑制、視覚認知行動機能の改善、および視覚機能強化
CN115038458A (zh) 嵌合视蛋白gpcr蛋白
WO2020038473A1 (zh) 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用
AU2024203852A1 (en) Method of enhancing viral-mediated gene delivery in the eye using proteosome inhibitors
JP2023510676A (ja) 光遺伝学的な用途のためのオプシン・シグナル伝達寿命の調節
KR20220003566A (ko) 신규한 유형의 효소 조성물
HK40108485A (en) Agent for restoring visual function or agent for preventing deterioration in visual function
HK40108486A (en) Agent for restoring visual function or agent for preventing deterioration in visual function
HK40108487A (en) Agent for restoring visual function or agent for preventing deterioration in visual function
HK40113233A (en) Agent for restoring visual function or agent for preventing deterioration in visual function
CN114144203A (zh) 源于显性变异基因的疾患的治疗剂
JP5174022B2 (ja) 膵臓β細胞増加促進剤及び膵臓β細胞増加促進組成物
CA3035651C (en) Agent for restoring visual function or agent for preventing deterioration in visual function
JP2026514979A (ja) Ｏｎ型双極細胞に効率的に標的させる複数プロモーターの遺伝子治療への使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190402

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190402

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20190410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190604

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20190703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200626

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200821

R150 Certificate of patent or registration of utility model

Ref document number: 6757024

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250